Drug Profile
Research programme: monoclonal antibody therapeutics - CytImmune Sciences
Alternative Names: CYT-91000Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CytImmune Sciences
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 20 Nov 2008 Preclinical trials in Cancer in USA (Parenteral)